MYDR24 is revolutionizing healthcare delivery by providing 24/7 access to premium home healthcare, advanced telemedicine, and a seamlessly integrated medical ecosystem. The startup combines personalized care with state-of-the-art technology, ensuring patients receive timely, efficient, and compassionate support—wherever they are, whenever they need it.
At the heart of this transformation is the MYDR24 platform—a dynamic digital interface that connects patients directly to certified doctors around the clock. Enhancing this offering is ACCUFLY, a specialized arm of the company that delivers air ambulance services and global medical tourism solutions, proving that critical care truly transcends borders.
Grounded in deep expertise across patient care management, nursing coordination, and emergency nursing, MYDR24 takes a hands-on, outcome-driven approach to healthcare. From urgent interventions to post-treatment continuity, the startup consistently delivers excellence at every stage of the patient journey.
In an exclusive interaction with The Interview World at the PRAGATI Founders Forum 2025—hosted by iHub-AWaDH at IIT Ropar—Rahul Kumar, Founder and Director of MYDR24 and ACCUFLY Healthcare Services, unveiled the innovations fuelling the startup’s momentum. He shared insights on how MYDR24 is leveraging data-driven healthcare, the precision of its analytics, and the expansive growth opportunities ahead. Most importantly, he outlined a bold long-term vision for transforming patient care at scale.
Here are the key takeaways from this compelling conversation.
Q: Can you share the key innovations your organization is driving in the healthcare space, and how these are translating into improved services and solutions for patients?
A: Our startup, MYDR24 Healthcare, operates under the aegis of ACCUFLY Healthcare Private Limited and is currently affiliated with IIIT Delhi. We are driven by a singular mission—to harness data intelligence and bridge critical gaps in India’s healthcare ecosystem.
At the core of our innovation lies a proactive approach to diagnostics. We analyze patient healthcare data at an early stage, conducting symptom-based assessments to detect diseases before they progress. This early intervention model enables timely and effective treatment, addressing one of the most pressing challenges in modern healthcare—late diagnosis.
In parallel, we are tackling a second major issue: the fragmented and often neglected state of rural healthcare. Through strategic integration, we are creating a robust bridge between underserved rural areas and the more structured urban healthcare infrastructure.
Moreover, in response to the rise of lifestyle-related conditions, we’ve prioritized rapid response solutions for heart attacks and strokes—conditions increasingly prevalent due to sedentary urban living.
Our model delivers instant medical services in tier 1 cities while extending advanced, accessible care to tier 3 regions. In doing so, MYDR24 is not just offering healthcare—we are reimagining its delivery, creating a unified system that ensures no patient is left behind, regardless of geography.
Q: What is your perspective on the growth potential and opportunities for this type of technology in the Indian market?
A: Our instant medical services address a glaring gap in the market—one that no competitor currently fills.
While major players like Apollo and Tata 1MG dominate the e-commerce and consultation space, they stop short at transactional care. They do not engage in proactive analysis of healthcare data, nor do they offer early diagnostic insights. This is where we differentiate ourselves.
We harness deep tech, particularly AI-driven data analytics, to bridge critical healthcare gaps—not just in rural areas, but in underserved urban populations as well. Our focus is clear: enable early diagnosis and provide end-to-end healthcare solutions.
Simply put, my mission is to detect problems before they escalate and deliver a complete, personalized healthcare journey—from symptom to solution.
Q: How accurate are the insights generated by your analytics platform based on the patient data you collect?
A: Our data accuracy stands at an exceptional 96 to 98 percent—because we rely on firsthand patient data.
Unlike others who import diagnostic results from third-party sources, we collect information directly from patients. This includes daily diagnostics such as blood tests, MRIs, CT scans, X-rays, and urine analyses. By working with real-time, primary data, we ensure unmatched precision in our analysis.
More importantly, we don’t just detect diseases early—we act on them. We use this data to design a comprehensive treatment plan tailored to each patient. From initial medication to doctor consultations, surgical planning, and post-operative care, we deliver a seamless, end-to-end healthcare solution.
Q: Can you outline your company’s long-term roadmap and the key milestones you aim to reach in the coming decade?
A: Over the next 5 to 10 years, I project a valuation exceeding ₹1,000 to ₹2,000 crore.
The momentum is already building. At Startup Mahakumbh, over 25 investors expressed strong interest in our venture. I’m currently in active discussions with 22 of them.
Following the recent launch of our MVP, investor confidence has only strengthened—some are already considering commitments as high as $1 million.
Meanwhile, I am actively engaged with IIIT Delhi, and our startup was ranked among the top 25 out of more than 700 entries in IIT Ropar’s prestigious PRAGATI scheme.
In parallel, the CEO of SRM Institute personally approached me to explore collaboration under the BioNest scheme. Our incubation journey with IIT Delhi is also progressing successfully, with significant traction in deep tech initiatives underway. The ecosystem is responding—and we’re moving swiftly to capitalize on every opportunity.
